The design of the panel included genes that provide information about COO, and the expression of MYC/BCL2 and other genes already known to predict OS and PFS in DLBCL cases [11, 20, 22, 24, 29, 38–42]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.